(lp0
(lp1
S'Reuters news'
p2
aS'released article On'
p3
aS'Tuesday'
p4
aa(lp5
S'BSX'
p6
aS'may near'
p7
aS'may deal buy'
p8
aa(lp9
S'Endo Pharmaceuticals'
p10
aS'has'
p11
aS'American Medical Systems'
p12
aa(lp13
S'deal'
p14
aS'be finalized in'
p15
aS'upcoming weeks'
p16
aa(lp17
S'deal'
p18
aS'value'
p19
ag12
aa(lp20
g12
aS'was acquired by'
p21
ag10
aa(lp22
g12
aS'generates'
p23
aS'estimated annual EBIT of about $ 160M'
p24
aa(lp25
g12
aS'has'
p26
aS'annual sales of about $ 500M'
p27
aa(lp28
g12
aS'makes'
p29
aS'vaginal mesh for gynecology indications'
p30
aa(lp31
S'acquisition'
p32
aS'be'
p33
aS'favorable'
p34
aa(lp35
S'BSX'
p36
aS'deal by'
p37
aS'debt'
p38
aa(lp39
S'deal'
p40
aS'would take'
p41
aS'BSX'
p42
aa(lp43
g12
aS'creating'
p44
aS'opportunity for significant deal synergies'
p45
aa(lp46
S'recovery'
p47
aS'is in'
p48
aS"BSX 's core cardiology businesses"
p49
aa(lp50
S'BSX'
p51
aS'in'
p52
aS'core cardiology businesses'
p53
aa(lp54
S'accretive acquisition'
p55
aS'would provide'
p56
aS'further leg up'
p57
aa(lp58
S'probability'
p59
aS'happening at'
p60
aS'50 %'
p61
aa(lp62
S'reason'
p63
aS'reflect'
p64
aS'lifting of litigation overhang following settlement of JNJ/Guidant litigation'
p65
aa(lp66
S'BSX'
p67
aS'remains'
p68
aS'uniquely positioned'
p69
aa(lp70
S'few med tech companies'
p71
aS'is with'
p72
aS'organic operating margin expansion opportunity'
p73
aa(lp74
S'BSX'
p75
aS'has finally turned corner from'
p76
aS'operational perspective'
p77
aa(lp78
g75
aS'gaining'
p79
aS'share'
p80
aa(lp81
S'Key pipeline approvals'
p82
aS'expected in'
p83
aS'2015'
p84
aa(lp85
S'Key pipeline approvals'
p86
aS'include'
p87
aS'Synergy DES'
p88
aa(lp89
g75
aS'achieve premium valuation to'
p90
aS'sector'
p91
aa(lp92
S'settlement'
p93
aS'allow'
p94
aS'BSX'
p95
aa.